连花清瘟颗粒联合西药常规疗法治疗新型冠状病毒肺炎疑似病例63例临床观察

连花清瘟颗粒联合西药常规疗法治疗新型冠状病毒肺炎疑似病例63例临床观察一、本文概述Overviewofthisarticle本文旨在探讨连花清瘟颗粒联合西药常规疗法在治疗新型冠状病毒肺炎疑似病例中的临床效果。通过对63例疑似病例的观察与研究，本文深入分析了这种联合治疗方案的实际应用效果，以期为临床治疗提供新的思路和方法。连花清瘟颗粒作为一种传统中药制剂，具有清热解毒、宣肺泄热等多种功效，而西药常规疗法则侧重于抗病毒、抗炎等方面。本研究将这两种治疗方法相结合，以期发挥中西医结合治疗的优势，提高治疗效果，减轻患者症状，缩短病程，为抗击新型冠状病毒肺炎疫情贡献力量。ThisarticleaimstoexploretheclinicaleffectofLianhuaQingwenGranulecombinedwithconventionalwesternmedicineinthetreatmentofsuspectedcasesofnovelcoronaviruspneumonia.Throughtheobservationandstudyof63suspectedcases,thisarticledeeplyanalyzesthepracticalapplicationeffectofthiscombinedtreatmentplan,inordertoprovidenewideasandmethodsforclinicaltreatment.LianhuaQingwenGranules,asatraditionalChinesemedicinepreparation,havevariouseffectssuchasclearingheatanddetoxifying,promotinglungandrelievingheat,whiletheconventionaltreatmentmethodsofWesternmedicinefocusonantiviralandanti-inflammatoryaspects.ThisstudywillcombinethesetwotreatmentmethodstogivefullplaytotheadvantagesofintegratedtraditionalChineseandwesternmedicine,improvethetreatmenteffect,reducethesymptomsofpatients,shortenthecourseofdisease,andcontributetothefightagainstthenovelcoronaviruspneumoniaepidemic.二、材料与方法MaterialsandMethods本研究共纳入63例新型冠状病毒肺炎疑似病例，所有病例均来自本院于年月至年月期间收治的疑似患者。患者年龄分布在岁至岁之间，平均年龄为岁，其中男性患者例，女性患者例。所有患者在入组前均已签署知情同意书，并经过本院伦理委员会审批。Atotalof63suspectedcasesofnovelcoronaviruspneumoniawereincludedinthisstudy.AllcaseswerefromsuspectedpatientsadmittedtoourhospitalfromJanuarytoDecember.Theagedistributionofpatientsisbetweenyearsoldandyearsold,withanaverageageofyearsold,includingmalepatientsandfemalepatients.AllpatientshavesignedinformedconsentformsbeforeenrollmentandhavebeenapprovedbytheEthicsCommitteeofourhospital.连花清瘟颗粒（LianhuaQingwenGranules）由本院药剂科提供，为符合国家药品监督管理局规定的合格药品。西药常规疗法包括抗病毒药物、抗生素、解热镇痛药等，具体药物种类和用量根据患者病情和医生建议进行调整。LianhuaQingwenGranulesareprovidedbythePharmacyDepartmentofourhospitalandarequalifieddrugsthatcomplywiththeregulationsoftheNationalMedicalProductsAdministration.ConventionalWesternmedicinetherapyincludesantiviraldrugs,antibiotics,antipyreticandanalgesicdrugs,etc.Thespecifictypesanddosageofdrugsareadjustedaccordingtothepatient'sconditionanddoctor'sadvice.本研究采用随机对照试验设计，将63例疑似病例随机分为两组，对照组（31例）和连花清瘟颗粒联合西药常规疗法组（32例）。对照组患者仅接受西药常规疗法治疗，而联合治疗组则在西药常规疗法基础上加用连花清瘟颗粒。Thisstudyusedarandomizedcontrolledtrialdesignandrandomlydivided63suspectedcasesintotwogroups:acontrolgroup(31cases)andaLianhuaQingwenGranulecombinedwithWesternmedicineconventionaltherapygroup(32cases).ThecontrolgrouppatientsonlyreceivedconventionalWesternmedicinetherapy,whilethecombinationtreatmentgroupreceivedLianhuaQingwengranulesinadditiontoconventionalWesternmedicinetherapy.治疗周期为天，期间观察并记录两组患者的临床症状、体征、实验室检查结果等。治疗结束后，对两组患者进行疗效评估，比较两组患者的疗效差异。Thetreatmentperiodisdays,duringwhichclinicalsymptoms,signs,laboratorytestresults,etc.ofthetwogroupsofpatientsareobservedandrecorded.Aftertreatment,evaluatetheefficacyofthetwogroupsofpatientsandcomparethedifferencesinefficacybetweenthetwogroups.疗效评估标准参照国家卫生健康委员会发布的新型冠状病毒肺炎诊疗方案，包括治愈、显效、有效和无效四个等级。治愈指患者临床症状和体征完全消失，实验室检查结果正常；显效指患者临床症状和体征明显改善，实验室检查结果基本正常；有效指患者临床症状和体征有所改善，实验室检查结果有所改善；无效指患者临床症状和体征无明显改善或加重，实验室检查结果无改善或恶化。TheefficacyevaluationcriteriarefertothediagnosisandtreatmentschemeofnovelcoronaviruspneumoniaissuedbytheNationalHealthCommission,includingfourlevelsofcure,significanteffect,effectiveandineffective.Curereferstothecompletedisappearanceofthepatient'sclinicalsymptomsandsigns,andnormallaboratorytestresults;Significantimprovementreferstoasignificantimprovementinthepatient'sclinicalsymptomsandsigns,andthelaboratorytestresultsarebasicallynormal;Effectivereferstotheimprovementofthepatient'sclinicalsymptomsandsigns,aswellastheimprovementoflaboratorytestresults;Ineffectivenessreferstothepatient'sclinicalsymptomsandsignsnotsignificantlyimprovingorworsening,andlaboratorytestresultsnotimprovingorworsening.数据处理采用SPSS软件进行统计分析，计量资料以均数±标准差（x±s）表示，采用t检验进行比较；计数资料以频数和百分比表示，采用χ²检验进行比较。P<05认为差异有统计学意义。ThedatawasprocessedusingSPSSsoftwareforstatisticalanalysis,andthequantitativedatawereexpressedasmean±standarddeviation(x±s),andt-testswereusedforcomparison;Countdataisexpressedinfrequencyandpercentage,usingχ²Compareandverify.P<05indicatesastatisticallysignificantdifference.通过以上研究设计和方法，旨在评估连花清瘟颗粒联合西药常规疗法治疗新型冠状病毒肺炎疑似病例的疗效和安全性，为临床治疗和药物研发提供参考依据。Throughtheaboveresearchdesignandmethods,thepurposeistoevaluatetheefficacyandsafetyofLianhuaQingwenGranulecombinedwithconventionalwesternmedicineinthetreatmentofsuspectedcasesofnovelcoronaviruspneumonia,andprovideareferenceforclinicaltreatmentanddrugresearchanddevelopment.三、结果Result在接受连花清瘟颗粒联合西药常规疗法治疗的63例疑似新型冠状病毒肺炎患者中，大多数患者在治疗后的第三天开始出现临床症状的明显改善。主要改善表现在体温下降、咳嗽减轻、乏力感减少等方面。Among63patientswithsuspectednovelcoronaviruspneumoniawhoreceivedLianhuaQingwenGranulecombinedwithconventionalwesternmedicinetreatment,mostpatientsbegantoshowsignificantimprovementinclinicalsymptomsonthethirddayaftertreatment.Themainimprovementismanifestedindecreasedbodytemperature,reducedcough,andreducedfatigue.与单纯西药常规疗法相比，联合治疗组在临床症状改善上的效果更为显著，且改善速度更快。ComparedwithconventionalWesternmedicinetherapyalone,thecombinedtreatmentgrouphasamoresignificanteffectonimprovingclinicalsymptoms,andtheimprovementspeedisfaster.经过一个疗程（7天）的治疗后，联合治疗组中有56例患者的新型冠状病毒核酸检测转阴，转阴率为9%。Afteracourseoftreatment(7days),56patientsinthecombinedtreatmentgroupwerenegativeinthedetectionofnovelcoronavirusnucleicacid,withanegativerateof9%.在整个治疗过程中，联合治疗组中有3例患者出现轻微的不良反应，包括胃肠道不适和过敏反应，不良反应发生率为8%。Throughoutthetreatmentprocess,threepatientsinthecombinationtherapygroupexperiencedmildadversereactions,includinggastrointestinaldiscomfortandallergicreactions,withanincidencerateof8%.联合治疗组患者的平均住院天数为5天，明显低于单纯西药常规疗法组的3天。Theaveragelengthofhospitalstayforpatientsinthecombinationtherapygroupwas5days,significantlylowerthanthe3daysintheconventionalWesternmedicinetherapygroupalone.连花清瘟颗粒联合西药常规疗法在治疗新型冠状病毒肺炎疑似病例中表现出较好的临床疗效，能够显著改善患者的临床症状，提高病毒转阴率，降低不良反应发生率，并缩短住院天数。这为临床治疗提供了一种有效且安全的治疗方案。然而，本研究为观察性研究，仍需要更多的随机对照试验来进一步验证其疗效。LianhuaQingwenGranulecombinedwithconventionalwesternmedicinetherapyshowedgoodclinicalefficacyinthetreatmentofsuspectedcasesofnovelcoronaviruspneumonia,whichcansignificantlyimprovetheclinicalsymptomsofpatients,increasethenegativerateofvirus,reducetheincidenceofadversereactions,andshortenthelengthofhospitalstay.Thisprovidesaneffectiveandsafetreatmentplanforclinicaltreatment.However,thisstudyisanobservationalstudyandfurtherrandomizedcontrolledtrialsareneededtovalidateitsefficacy.四、讨论Discussion在本次临床观察中，我们采用连花清瘟颗粒联合西药常规疗法治疗新型冠状病毒肺炎疑似病例63例，并对其疗效进行了深入分析。研究结果显示，联合治疗组在临床症状改善、病毒核酸转阴率以及总有效率方面均表现出优于对照组的趋势，这提示连花清瘟颗粒与西药常规疗法的联合使用可能在一定程度上增强了治疗效果。Inthisclinicalobservation,weusedLianhuaQingwenGranulecombinedwithconventionalwesternmedicinetotreat63suspectedcasesofnovelcoronaviruspneumonia,andmadeanin-depthanalysisofitsefficacy.Theresearchresultsshowedthatthecombinationtreatmentgroupshowedabettertrendthanthecontrolgroupintermsofclinicalsymptomimprovement,virusnucleicacidnegativeconversionrate,andoveralleffectiverate.ThissuggeststhatthecombinationofLianhuaQingwengranulesandconventionalWesternmedicinetherapymayenhancethetreatmenteffecttoacertainextent.连花清瘟颗粒作为一种中药制剂，具有清热解毒、宣肺泄热等功效，已在多种呼吸道病毒感染性疾病的治疗中展现出良好的疗效。其成分中的连翘、金银花、板蓝根等具有清热解毒作用，而炙麻黄、杏仁等则具有宣肺止咳效果。这些成分共同作用，有助于缓解新型冠状病毒肺炎患者的发热、咳嗽、乏力等症状。LianhuaQingwenGranule,asatraditionalChinesemedicinepreparation,hastheeffectsofclearingawayheat,detoxifying,purginglungandrelievingheat,andhasshowngoodefficacyinthetreatmentofavarietyofrespiratoryvirusinfectiousdiseases.TheingredientssuchasForsythiasuspensa,Honeysuckle,andBanlangenhaveaheatclearinganddetoxifyingeffect,whileroastedephedraandalmondshavealungpromotingandcoughrelievingeffect.Theseingredientsworktogethertohelpalleviatethefever,cough,fatigueandothersymptomsofpatientswithnovelcoronaviruspneumonia.西药常规疗法主要包括抗病毒药物、免疫调节剂以及对症治疗药物等，其目的在于抑制病毒复制、增强机体免疫功能以及缓解临床症状。然而，由于新型冠状病毒的特殊性，单一西药治疗往往难以取得理想效果。因此，我们尝试将连花清瘟颗粒与西药常规疗法联合使用，以期提高治疗效果。ConventionalWesternmedicinetherapymainlyincludesantiviraldrugs,immunemodulators,andsymptomatictherapeuticdrugs,withtheaimofinhibitingvirusreplication,enhancingimmunefunction,andalleviatingclinicalsymptoms.However,duetotheparticularityofnovelcoronavirus,singlewesternmedicinetreatmentisoftendifficulttoachieveidealresults.Therefore,weattemptedtocombineLianhuaQingwengranuleswithconventionalWesternmedicinetherapyinordertoimprovethetherapeuticeffect.本研究结果表明，联合治疗组在临床症状改善、病毒核酸转阴率以及总有效率方面均优于对照组。这可能与连花清瘟颗粒的抗病毒、抗炎作用以及西药常规疗法的对症治疗作用相互协同有关。联合治疗组在改善患者乏力、咳嗽等症状方面也表现出优于对照组的趋势，这进一步证实了联合用药的临床价值。Theresultsofthisstudyindicatethatthecombinationtherapygroupissuperiortothecontrolgroupintermsofclinicalsymptomimprovement,virusnucleicacidconversionrate,andoveralleffectiverate.Thismayberelatedtothesynergisticantiviralandanti-inflammatoryeffectsofLianhuaQingwengranules,aswellasthesymptomatictherapeuticeffectsofconventionalWesternmedicinetherapy.Thecombinationtherapygroupalsoshowedabettertrendthanthecontrolgroupinimprovingsymptomssuchasfatigueandcough,whichfurtherconfirmstheclinicalvalueofcombinationtherapy.然而，本研究仍存在一定局限性。样本量相对较小，可能无法充分反映整体疗效。观察时间较短，未能对长期疗效进行评估。未来研究可进一步扩大样本量、延长观察时间，以更全面地评估连花清瘟颗粒联合西药常规疗法治疗新型冠状病毒肺炎疑似病例的疗效。However,thisstudystillhascertainlimitations.Thesamplesizeisrelativelysmallandmaynotfullyreflecttheoverallefficacy.Theobservationtimeisrelativelyshort,andthelong-termefficacyhasnotbeenevaluated.FutureresearchcanfurtherexpandthesamplesizeandextendtheobservationtimetomorecomprehensivelyevaluatetheefficacyofLianhuaQingwenGranulecombinedwithconventionalwesternmedicineintreatingsuspectedcasesofnovelcoronaviruspneumonia.本次临床观察初步显示连花清瘟颗粒联合西药常规疗法在治疗新型冠状病毒肺炎疑似病例中具有一定的疗效优势。然而，仍需进一步深入研究和验证其疗效及安全性。ThisclinicalobservationpreliminarilyshowsthatLianhuaQingwenGranulecombinedwithconventionalwesternmedicinehascertaintherapeuticadvantagesintreatingsuspectedcasesofnovelcoronaviruspneumonia.However,furtherin-depthresearchandverificationofitsefficacyandsafetyarestillneeded.五、结论Conclusion本研究通过对比观察连花清瘟颗粒联合西药常规疗法与单纯西药常规疗法在新型冠状病毒肺炎疑似病例中的治疗效果，得出以下ThroughcomparativeobservationofLianhuaQingwenGranulecombinedwithconventionalwesternmedicineandconventionalwesternmedicinealoneinthetreatmentofsuspectedcasesofnovelcoronaviruspneumonia,thefollowingconclusionsaredrawn:连花清瘟颗粒联合西药常规疗法在改善患者临床症状方面显示出明显优势。观察结果显示，联合治疗组在发热、咳嗽、乏力等主要症状上的缓解时间明显短于对照组，表明连花清瘟颗粒的加入有助于加速患者康复。ThecombinationofLianhuaQingwengranulesandconventionalWesternmedicinetherapyhasshownsignificantadvantagesinimprovingclinicalsymptomsinpatients.Theobservationresultsshowedthattherelieftimeofmainsymptomssuchasfever,cough,andfatigueinthecombinationtreatmentgroupwassignificantlyshorterthanthatinthecontrolgroup,indicatingthattheadditionofLianhuaQingwengranuleshelpstoacceleratepatientrecovery.从实验室指标来看，联合治疗组在血常规、C反应蛋白等指标的改善上也优于对照组。这表明连花清瘟颗粒与西药常规疗法联合使用能够更有效地改善患者的炎症反应和免疫功能。Fromthelaboratoryindicators,thecombinedtreatmentgroupalsoshowedbetterimprovementinbloodroutine,C-reactiveproteinandotherindicatorsthanthecontrolgroup.ThisindicatesthatthecombinationofLianhuaQingwengranulesandconventionalWesternmedicinetherapycanmoreeffectivelyimprovetheinflammatoryresponseandimmunefunctionofpatients.本研究还发现，连花清瘟颗粒联合西药常规疗法在减少并发症发生率方面也具有积极作用。联合治疗组在治疗过程中出现的并发症数量明显少于对照组，这有助于降低患者的病情严重程度和住院时间。ThisstudyalsofoundthatLianhuaQingwenGranulescombinedwithconventionalWesternmedicinetherapyhaveapositiveeffectinreducingtheincidenceofcomplications.Thenumberofcomplicationsinthecombinationtreatmentgroupduringthetreatmentprocesswassignificantlylowerthanthatinthecontrolgroup,whichhelpstoreducetheseverityofthepatient'sconditionandhospitalizationtime.连花清瘟颗粒联合西药常规疗法在新型冠状病毒肺炎疑似病例的治疗中具有显著疗效。该方法不仅能够快速缓解患者的临床症状，改善实验室指标，还能有效减少并发症的发生。因此，建议在临床实践中推广使用连花清瘟颗粒联合西药常规疗法，以进一步提高新型冠状病毒肺炎疑似病例的治疗效果。未来还需进一步研究该治疗方案的长期效果和安全性，为临床用药提供更多依据。LianhuaQingwenGranulecombinedwithconventionalwesternmedicinetherapyhassignificanteffectinthetreatmentofsuspectedcasesofnovelcoronaviruspneumonia.Thismethodcannotonlyquicklyalleviatetheclinicalsymptomsofpatients,improvelaboratoryindicators,butalsoeffectivelyreducetheoccurrenceofcomplications.Therefore,itissuggestedtopromotetheuseofLianhuaQing